A study of individuals buried in avalanches between 1981 and 2024 found that survival rate and rescue response time increased ...

While they were both approved several years back to treat the same two types of prostate cancer, Astellas and Pfizer’s Xtandi ...

Modern avalanche transceivers, shovels and probes are now standard in ski touring. Along with a rise in the uptake of ...

The American Cancer Society released its biennial update on breast cancer trends Tuesday, marking the start of Breast Cancer ...

The good news is that if you are diagnosed with cancer, mortality rates have increased. From 1991 to 2021, a 33 percent ...

Two strategies to de-escalate treatment for human papillomavirus (HPV)-positive oropharyngeal cancer failed to show ...

The trout, born on Halloween in 2023, were raised at the Roaring Fork Conservancy for almost a year before they were released ...

Patients with soft tissue sarcomas showed improved functional results, quality of life and fewer side effects when treated ...

The 12-month survival rates in patients with non-clear cell renal cell carcinoma showed improvements after treatment with ...

Lu-Dotatate may be considered “a rational therapeutic choice” for patients with refractory meningioma, according to Kenneth Merrell, MD.

A radionuclide agent, Lu-177 dotatate was approved by the FDA in 2018 for gastroenteropancreatic neuroendocrine tumors ...

A radiopharmaceutical therapy that has successfully extended progression-free survival for patients with neuroendocrine tumors shows early promise for delivering similar benefits to patients with ...